+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocrine And Metabolic Disorders Drugs Market Research Reports

Hypophosphatasia - Epidemiology Forecast-2034 - Product Thumbnail Image

Hypophosphatasia - Epidemiology Forecast-2034

  • Report
  • December 2024
  • 68 Pages
  • Global
From
Menkes Disease - Epidemiology Forecast - 2034 - Product Thumbnail Image

Menkes Disease - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 53 Pages
  • Global
From
Osteoporosis - Pipeline Insight, 2024 - Product Thumbnail Image

Osteoporosis - Pipeline Insight, 2024

  • Clinical Trials
  • December 2024
  • 80 Pages
  • Global
From
Antiphospholipid Syndrome (APS) - Epidemiology Forecast - 2034 - Product Thumbnail Image

Antiphospholipid Syndrome (APS) - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 79 Pages
  • Global
From
Prader-Willi Syndrome - Epidemiology Forecast - 2034 - Product Thumbnail Image

Prader-Willi Syndrome - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 80 Pages
  • Global
From
Diabetic Kidney Disease (DKD) - Epidemiology Forecast - 2034 - Product Thumbnail Image

Diabetic Kidney Disease (DKD) - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 95 Pages
  • Global
From
Cushing Syndrome - Pipeline Insight, 2024 - Product Thumbnail Image

Cushing Syndrome - Pipeline Insight, 2024

  • Drug Pipelines
  • November 2024
  • 60 Pages
  • Global
From
Type 2 Diabetes - Pipeline Insight, 2024 - Product Thumbnail Image

Type 2 Diabetes - Pipeline Insight, 2024

  • Drug Pipelines
  • November 2024
  • 240 Pages
  • Global
From
Diabetes - Pipeline Insight, 2024 - Product Thumbnail Image

Diabetes - Pipeline Insight, 2024

  • Clinical Trials
  • November 2024
  • 450 Pages
  • Global
From
Gout - Pipeline Insight, 2024 - Product Thumbnail Image

Gout - Pipeline Insight, 2024

  • Clinical Trials
  • November 2024
  • 80 Pages
  • Global
From
Graves' Disease - Pipeline Insight, 2024 - Product Thumbnail Image

Graves' Disease - Pipeline Insight, 2024

  • Drug Pipelines
  • November 2024
  • 60 Pages
  • Global
From
Pompe Disease - Pipeline Insight, 2024 - Product Thumbnail Image

Pompe Disease - Pipeline Insight, 2024

  • Clinical Trials
  • November 2024
  • 80 Pages
  • Global
From
Niemann-Pick disease - Pipeline Insight, 2024 - Product Thumbnail Image

Niemann-Pick disease - Pipeline Insight, 2024

  • Clinical Trials
  • November 2024
  • 60 Pages
  • Global
From
NLRP3 Protein Inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

NLRP3 Protein Inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • November 2024
  • 80 Pages
  • Global
From
From
22q11.2 Deletion Syndrome - Pipeline Insight, 2024 - Product Thumbnail Image

22q11.2 Deletion Syndrome - Pipeline Insight, 2024

  • Drug Pipelines
  • August 2024
  • 60 Pages
  • Global
From
Pheochromocytoma- Pipeline Insight, 2024 - Product Thumbnail Image

Pheochromocytoma- Pipeline Insight, 2024

  • Drug Pipelines
  • August 2024
  • 60 Pages
  • Global
From
Acute Pancreatitis - Pipeline Insight, 2024 - Product Thumbnail Image

Acute Pancreatitis - Pipeline Insight, 2024

  • Clinical Trials
  • August 2024
  • 60 Pages
  • Global
From
From
From
Loading Indicator

The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders. Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists. Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more